Supplementary tables

Table SI. Demographic data and tumor characteristics of the patients in the present study (n=4).

Characteristic	Value
Age	
Median (range), years	63 (52-72)
≤60 years	2 (50.0)
≥60 years	2 (50.0)
Sex	
Male	2 (50.0)
Female	2 (50.0)
Smoking history	
Yes	1 (25.0)
No	3 (75.0)
Drinking history	
Yes	1 (25.0)
No	3 (75.0)
Tumor location	
Gingiva	2 (50.0)
Tongue	2 (50.0)
TNM stage	
I-II	2 (50.0)
III-IV	2 (50.0)
Lymph node metastasis	
Positive (N+)	1 (25.0)
Negative (N0)	3 (75.0)

Data are presented as median (range) or n (%). TNM, tumor-node-metastasis.

Table SII. Oligonucleotides sequences.

sgRNA	Sequence (5'-3')
sgMETTL5-1	caccGAGAGAGTCGCCTGCAACAAGgttt
sgMETTL5-2	caccGTTTCACAAAAAGAAATCAGgttt

sg, small guide RNA; METTL5, methyltransferase 5, N6-adenosine.

Table SIII. Antibodies used in the present study.

Antibody	Source	Cat. no.	Dilution
Anti-METTL5	Invitrogen™; Thermo Fisher Scientific, Inc.	PA5-70061	1:1,000 (for western blotting); 1:100 (for IHC)
Anti-GAPDH	Proteintech Group, Inc.	10494-1-AP	1:2,000 (for western blotting)
Anti-CCND3	Proteintech Group, Inc.	26755-1-AP	1:1,000 (for western blotting)
Anti-Ki-67	Abcam	ab15580	1:500 (for IHC)
Goat Anti-Rabbit IgG H&L (HRP)	Abcam	ab205718	1:2,000 (for IHC)
Anti-rabbit IgG, HRP-linked Antibody	Cell Signaling Technology, Inc.	7074S	1:5,000 (for western blotting)

METTL5, methyltransferase 5, N6-adenosine; CCND3, cyclin D3; IHC, immunohistochemistry.